Investigating the genetic and epigenetic changes in bile duct cancer
Epigenetic Mechanisms of Biliary Epithelial Neoplasia
['FUNDING_R01'] · TULANE UNIVERSITY OF LOUISIANA · NIH-10626746
This study is looking into how a specific protein affects the growth of cholangiocarcinoma, a tough-to-treat bile duct cancer, to find new ways to improve treatments for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TULANE UNIVERSITY OF LOUISIANA (nih funded) |
| Locations | 1 site (NEW ORLEANS, UNITED STATES) |
| Trial ID | NIH-10626746 on ClinicalTrials.gov |
What this research studies
This research focuses on cholangiocarcinoma, a highly malignant cancer of the biliary tree, which is becoming increasingly common and lacks effective treatment options. The study aims to understand the molecular mechanisms behind this cancer, particularly the role of genetic and epigenetic changes that affect tumor growth. Researchers will explore how the EZH2 protein silences tumor suppressor genes and how this contributes to cancer progression. By examining these mechanisms, the research seeks to identify potential new therapies that could enhance existing treatments for patients with this type of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cholangiocarcinoma or those at high risk for developing this type of cancer.
Not a fit: Patients with other types of cancers unrelated to the biliary system may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve outcomes for patients with bile duct cancer.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic mechanisms in cancer treatment, suggesting that this approach may be effective.
Where this research is happening
NEW ORLEANS, UNITED STATES
- TULANE UNIVERSITY OF LOUISIANA — NEW ORLEANS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WU, TONG — TULANE UNIVERSITY OF LOUISIANA
- Study coordinator: WU, TONG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer, Epithelial cancer